PE20130228A1 - Heterociclilbencilpirazoles sustituidos - Google Patents

Heterociclilbencilpirazoles sustituidos

Info

Publication number
PE20130228A1
PE20130228A1 PE2012002121A PE2012002121A PE20130228A1 PE 20130228 A1 PE20130228 A1 PE 20130228A1 PE 2012002121 A PE2012002121 A PE 2012002121A PE 2012002121 A PE2012002121 A PE 2012002121A PE 20130228 A1 PE20130228 A1 PE 20130228A1
Authority
PE
Peru
Prior art keywords
methyl
compounds
formula
heterocyclylbenzylpyrazoles
substituted
Prior art date
Application number
PE2012002121A
Other languages
English (en)
Spanish (es)
Inventor
Michael Harter
Hartmut Beck
Susanne Greschat-Schade
Peter Ellinghaus
Kerstin Unterschemman
Joachim Schuhmacher
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44063276&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130228(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of PE20130228A1 publication Critical patent/PE20130228A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2012002121A 2010-05-08 2011-05-03 Heterociclilbencilpirazoles sustituidos PE20130228A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10004855 2010-05-08

Publications (1)

Publication Number Publication Date
PE20130228A1 true PE20130228A1 (es) 2013-03-15

Family

ID=44063276

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012002121A PE20130228A1 (es) 2010-05-08 2011-05-03 Heterociclilbencilpirazoles sustituidos

Country Status (26)

Country Link
US (2) US20130172311A1 (enExample)
EP (1) EP2569312B1 (enExample)
JP (1) JP5727002B2 (enExample)
KR (1) KR20130108997A (enExample)
CN (1) CN103003269B (enExample)
AR (1) AR081368A1 (enExample)
AU (1) AU2011252223A1 (enExample)
BR (1) BR112012028651A2 (enExample)
CA (1) CA2798375A1 (enExample)
CO (1) CO6640218A2 (enExample)
CR (1) CR20120570A (enExample)
CU (1) CU20120157A7 (enExample)
DO (1) DOP2012000284A (enExample)
EA (1) EA201291167A1 (enExample)
EC (1) ECSP12012288A (enExample)
ES (1) ES2462522T3 (enExample)
IL (1) IL222851A0 (enExample)
MA (1) MA34939B1 (enExample)
MX (1) MX2012012960A (enExample)
PE (1) PE20130228A1 (enExample)
PH (1) PH12012502202A1 (enExample)
SG (1) SG185459A1 (enExample)
TN (1) TN2012000531A1 (enExample)
TW (1) TW201200510A (enExample)
UY (1) UY33369A (enExample)
WO (1) WO2011141326A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2155904A2 (en) * 2007-05-01 2010-02-24 Hill's Pet Nutrition Inc. Methods and compositions for diagnosing osteoarthritis in a feline
KR20100016617A (ko) * 2007-05-18 2010-02-12 바이엘 쉐링 파마 악티엔게젤샤프트 과증식성 장애 및 혈관형성 관련 질환의 치료에 유용한 저산소증 유도성 인자 （ｈｉｆ）의 억제제
CN103003269B (zh) * 2010-05-08 2015-11-25 拜耳知识产权有限责任公司 取代的杂环基苄基吡唑及其用途
DK2867230T3 (da) 2012-07-02 2020-04-14 Monsanto Technology Llc Fremgangsmåde til fremstilling af 3,5-disubstitueret 1,2,4-oxadiazoler
RU2698197C2 (ru) 2012-08-24 2019-08-23 Боард Оф Регентс, Зе Юниверсити Оф Тексас Систем Гетероциклические модуляторы активности hif для лечения заболеваний
US20140073634A1 (en) * 2012-08-24 2014-03-13 Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center Heterocyclic modulators of hif activity for treatment of disease
WO2014031933A2 (en) * 2012-08-24 2014-02-27 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
DK3110420T3 (da) 2014-02-25 2019-05-13 Board Of Regents Univ Of Texas System Salte af heterocykliske modulatorer af hif-aktivitet til behandling af sygdomme
US10191597B2 (en) 2015-06-30 2019-01-29 Synaptics Incorporated Modulating a reference voltage to preform capacitive sensing
WO2018131657A1 (ja) * 2017-01-13 2018-07-19 日産化学工業株式会社 芳香族ジアミン化合物前駆体の製造方法
CN115944626B (zh) * 2022-12-08 2024-04-19 桂林医学院附属医院 小分子化合物在制备抗缺氧或缺血再灌注损伤药物中的应用
WO2025096654A1 (en) * 2023-10-30 2025-05-08 Pretzel Therapeutics, Inc. Compositions and inhibitors of polrmt

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610726B2 (en) * 2001-06-29 2003-08-26 North Shore-Long Island Jewish Research Institute Compositions and agents for modulating cellular proliferation and angiogenesis
WO2004089303A2 (en) 2003-04-03 2004-10-21 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
AU2004275694B2 (en) 2003-06-30 2008-03-06 Bizbiotech Co., Ltd. Compounds, compositions and methods
CN1842332A (zh) * 2003-06-30 2006-10-04 Hif生物公司 化合物、组合物及方法
GB0508472D0 (en) * 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
KR20100016617A (ko) * 2007-05-18 2010-02-12 바이엘 쉐링 파마 악티엔게젤샤프트 과증식성 장애 및 혈관형성 관련 질환의 치료에 유용한 저산소증 유도성 인자 （ｈｉｆ）의 억제제
DE102008057344A1 (de) * 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
WO2010054764A1 (de) * 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Heteroaromatische verbindungen zur verwendung als hif-inhibitoren
HRP20150341T1 (hr) * 2008-11-14 2015-05-08 Bayer Intellectual Property Gmbh Heterocikliäśki supstituirani spojevi arila kao inhibitori hif
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
US8389509B2 (en) 2009-01-23 2013-03-05 Bristol-Myers Squibb Company Substituted pyrazole compounds
CN103003269B (zh) * 2010-05-08 2015-11-25 拜耳知识产权有限责任公司 取代的杂环基苄基吡唑及其用途

Also Published As

Publication number Publication date
CO6640218A2 (es) 2013-03-22
MX2012012960A (es) 2012-12-17
US8470811B2 (en) 2013-06-25
PH12012502202A1 (en) 2013-02-04
EP2569312A1 (de) 2013-03-20
EA201291167A1 (ru) 2013-05-30
BR112012028651A2 (pt) 2016-08-09
DOP2012000284A (es) 2013-03-31
SG185459A1 (en) 2012-12-28
KR20130108997A (ko) 2013-10-07
IL222851A0 (en) 2012-12-31
JP2013526497A (ja) 2013-06-24
CU20120157A7 (es) 2013-03-27
EP2569312B1 (de) 2014-03-26
US20120028950A1 (en) 2012-02-02
US20130172311A1 (en) 2013-07-04
CN103003269B (zh) 2015-11-25
TN2012000531A1 (en) 2014-04-01
UY33369A (es) 2011-12-01
JP5727002B2 (ja) 2015-06-03
ECSP12012288A (es) 2012-12-28
AR081368A1 (es) 2012-08-29
TW201200510A (en) 2012-01-01
WO2011141326A1 (de) 2011-11-17
CN103003269A (zh) 2013-03-27
MA34939B1 (fr) 2014-03-01
AU2011252223A1 (en) 2012-12-06
ES2462522T3 (es) 2014-05-23
CR20120570A (es) 2013-04-22
CA2798375A1 (en) 2011-11-17

Similar Documents

Publication Publication Date Title
PE20130228A1 (es) Heterociclilbencilpirazoles sustituidos
DOP2021000183A (es) Compuestos tricíclicos condensados útiles como agentes anticancerígenos
PE20180929A1 (es) Analogos novedosos de nucleosidos sustituidos en el anillo aromatico biciclico 6-6 para su uso como inhibidores de prmt5
PE20130155A1 (es) Derivados de ariletinilo
PE20130235A1 (es) Derivados de aminopirimidina como moduladores de la lrrk2
AR090760A1 (es) Compuestos de benzotiazol y su uso contra el virus de hiv
CL2013001600A1 (es) Compuestos derivados de acidos 1-bencilcicloalquilcarboxilicos sustituidos; procedimiento de preparacion de dichos compuestos; medicamento que los contiene; y su uso para el tratamiento y/o la prevencion de insuficiencia cardiaca, angina pectoris, hipertonia, afecciones tromboembolicas, insuficiencia renal, entre otras.
PE20141598A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
PE20180318A1 (es) Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
CL2013000083A1 (es) Compuestos derivados de pirimidinas y triazinas condensadas; procedimiento para prepararlos; medicamento que los comprende; procedimiento de tratamiento y/o prevencion; y su uso para el tratamiento y/o prevencion de insuficiencia cardiaca, angina de pecho, hipertension, hipertension pulmonar e isquemias, entre otras enfermedades.
BR112012019762A2 (pt) composto, composição, e, método para tratar uma doença.
PE20161243A1 (es) Compuesto heterociclico fusionado
EA201501122A1 (ru) Новые агонисты соматостатиновых рецепторов подтипа 4 (sstr4)
ECSP12011684A (es) Inhibidores de los virus flaviviridae.
CL2022000374A1 (es) Métodos para preparar análogos de incretina
PE20200342A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
PE20160589A1 (es) Heteroaril-ciclohexil-tetraazabenzo[e]azulenos como antagonistas de los receptores de vasopresina v1a
CL2012003132A1 (es) Compuestos derivados de heteroaril-ciclohexil-tetraazabenzo[e]azulenos, antagonistas del receptor de la vla; proceso de preparacion; composicion farmaceutica; y su uso para la prevencion o tratamiento de dismenorrea, disfuncion sexual masculina o femenina, hipertension y cirrosis hepatica, entre otros.
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
PE20141000A1 (es) Ureas asimetricas y usos medicos de las mismas
DOP2020000118A (es) Proceso para la preparación de derivados de quinolina
CO6230986A2 (es) Compuesto de 4-piridinona y su uso para cancer
PE20141556A1 (es) Derivados de etinilo como moduladores alostericos de mglur5
CL2015001319A1 (es) Compuestos derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; y metodo para la preparacion de compuestos.
EA201401259A1 (ru) Фторированные мостиковые производные спиро[2,4]гептана в качестве агонистов рецептора alx

Legal Events

Date Code Title Description
FD Application declared void or lapsed